Patients with LC should undergo regular HCC surveillance even during NAs therapy. Disclosures: Namiki Izumi – Speaking and Teaching: MSD Co., Chugai Co., Daiichi Sankyo Co., Bayer Co., Bristol Meyers Co. The following people have nothing to disclose: Etsuro Orito, Chitomi Hasebe, Masayuki Kurosaki, Atsunori Kusakabe, Yukio Osaki Background and Aims: Increased risk of renal proximal tubular injury resulting in decreased urinary phosphate reabsorption

and osteoporosis has been reported in HIV patients treated with tenofovir (TDF). Goals of this study were to evaluate the prevalence of abnormal renal phosphate wasting and abnormal bone mineral density (BMD) in a cohort of chronic hepatitis B (CHB) patients HM781-36B molecular weight taking TDF compared to CHB patients treated with entecavir (ETV) and untreated CHB patients. Patients and Methods: Cross-sectional study of 146 consecutive Asian-American CHB patients who were treatment naïve or treated with either TDF or ETV. Assignment of anti-viral agent was at the discretion of the physician. Testing included fasting blood and urinary levels of phosphate and creatinine to assess proximal tubular handling of phosphate by measuring maximal rate of tubular reabsorption

of phosphate (TmPO4) over glomerular filtration rate (GFR) (TmPO4/GFR). Abnormal TmPO4/GFR) was defined as < 2.8-4.4 mg/dL. BMD of the lumbar spine (from L1-L4) and hip was measured using dual X-ray absorptiometry (DEXA). Results: TmPO4/GFR was similar among

CHB patients treated with TDF (n=42) selleck kinase inhibitor compared to untreated patients (n=60) and patients taking ETV (n=44). However, among patients treated with > 1 8 months of TDF or ETV, the prevalence of abnormal TmPO4/GFR was higher among patients treated with TDF MCE compared to ETV patients (48.5% (16/33) vs. 12.5% (3/24), p=0.005). Overall prevalence of osteoporosis (T score < -2.5) in this cohort of CHB patients was 14%, with no significant difference between the 3 groups. Patients with osteoporosis were older, had lower BMIs and higher serum alkaline phosphatase levels. There was no association with treatment or type of treatment and the presence of osteoporosis. Renal phosphate handling did not correlate with osteoporosis in this CHB cohort. The proportion of patients who had suffered fractures was uniformly low (< 5%) in all three groups. Conclusions: CHB patients treated > 1 8 months of TDF experienced an increased risk of proximal tubular dysfunction assessed by TmPO4/GFR. No clinical effects of abnormal TmPO4/GFR were seen. TDF did not increase the risk of osteoporosis or impaired creatinine clearance. Larger, preferably long term longitudinal studies are needed to confirm these findings. Phosphate Handling, Renal Function and Osteoporosis By Treatment Group Parameter Total N=146 No Treatment N=60 ETV N=44 TDF N=42 p value Phosphate threshold for renal tubular resorption Mean±SD % (n)<2.8 mg/dL 3.0±0.5 32% (46) 3.0+0.